Business Standard

Strides Pharma announces JV with Chinese firm to launch its products

The development comes in the backdrop of the recent regulatory developments in China which has enabled fast track approvals of differentiated high-quality generics approved in key regulated markets

Strong triggers for Strides Shasun
Premium

Gireesh Babu Chennai
Strides Pharma Science Limited has announced entry into Chinese market through a Joint Venture between its Singapore-based step down subsidiary Strides Pharma Global Pte (SPG) and Sun Moral International (HK) Limited, a wholly-owned subsidiary of Sihuan Pharmaceutical Holdings Group Ltd (Sihuan), one of China’s leading pharmaceutical companies. 

China is the second-largest pharmaceutical market with a $137 billion market opportunity. Sihuan has a market share of 8.3 per cent in the cardio-cerebral vascular market and presence in other therapeutic areas.

“We look forward to strengthening the partnership in the near term to build a strong pharmaceutical franchise in China,” said Strides

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Jul 29 2019 | 9:57 PM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com